Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (355)	10/18/2000 1:05:58 PM
From: Geigartt	Respond to of 1833

Richard: Thanks for the list. Re: "Concept stock" My definition Concept stocks are scary because by concept I mean companies valued for their new, unproven product or technolgy. They have lots of debt because they have no earnings yet. Therefore, it is a very subjective play, determining whether the concept or techn. is useful. They are therefore cheap but RISKY. And who knows when the concept will be recognized, maybe never. And if no one sees the value, it may never take off, and you are hanging there waiting while someone else makes the techn obsolete. TCLN is one. I try to find them and watch for volume and price spikes. I don't know anyone who has real knowledge of the products and anyone who does is an insider. So . . ., But if they have some cash, or some other redeeming value, there is some (I emphasize "some") downside protection. Always looking; always do your own research. Steve

To: scaram(o)uche who wrote (355)	10/20/2000 9:35:59 AM
From: scaram(o)uche	Respond to of 1833

biz.yahoo.com Friday October 20, 6:44 am Eastern Time Press Release SOURCE: Biacore Biacore: Interim Report January-September 2000 LONDON, Oct. 20 /PRNewswire/ -- The following press release was issued today by Biacore (Nasdaq: BCOR - news): -- Biacore's rapid growth continues. Sales increased by 35% in the year to-date and by 46% in the 3rd Quarter. -- Strong U.S. revenue growth driven by pharmaceutical and biotech customers, as SPR technology gains further acceptance as a key drug discovery tool. -- Operating income increased by 64% year to-date. -- Investment in Biacore's unique high throughput SPR array chip technology initiated. Collaboration with Millennium Pharmaceuticals progressing well. Considerable increase in R&D investment anticipated in 2001. -- For the full-year 2000, a sales increase in the range of 25-30% is expected. The previous forecast indicated an increase in the range of 20%. (snip)